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Abstract
Vitamin D (Vit D) deficiency is a common condition in chronic kidney disease (CKD) patients that negatively affects bone
regeneration and fracture healing. Previous study has shown that timely healing of titanium implants is impaired in CKD.
This study aimed to investigate the effect of Vit D supplementation on implant osseointegration in CKD mice. Uremia was
induced by 5/6 nephrectomy in C57BL mice. Eight weeks after the second renal surgery, animals were given 1,25(OH)2D3
three times a week intraperitoneally for four weeks. Experimental titanium implants were inserted into the distal end of
femurs two weeks later. Serum measurements confirmed decreased 1,25(OH)2D levels in CKD mice, which could be
successfully corrected by Vit D injections. Moreover, the hyperparathyroidism observed in CKD mice was also corrected. X-
ray examination and histological sections showed successful osseointegration in these mice. Histomorphometrical analysis
revealed that the bone-implant contact (BIC) ratio and bone volume (BV/TV) around the implant were significantly increased
in the Vit D-supplementation group. In addition, resistance of the implant, as measured by a push-in method, was
significantly improved compared to that in the vehicle group. These results demonstrate that Vit D supplementation is an
effective approach to improve the fixation of titanium implants in CKD.
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Introduction
Chronic kidney disease (CKD) is recognized as a global public
health threat. It is a highly prevalent disease with severe
complications, such as cardiovascular disease and chronic kidney
disease-mineral and bone disorders (CKD-MBD) [1–3]. Screening
conducted by nephrologists from all over the world indicates that
the incidence of CKD is increasing with ranges of 10.2% to 20%
of the population [4–7]. According to a recent cross-sectional
survey in China, the prevalence of CKD adults was 10.8%, which
means that approximately 119.5 million people are affected by
CKD in this rapidly developing country [8].
Declining renal function negatively affects the status of oral
health. A recent systematic review showed that poor oral health is
a common and often severe side-effect for adults with CKD [9].
Approximately 90% of CKD patients suffer from oral symptom-
s,including both hard and soft tissues [10–14]. Studies have
demonstrated that CKD profoundly influences bone remolding
[15] and the structure of the mandible [16]. Furthermore, cross-
sectional radiographic examinations indicate that CKD patients
experience much more severe alveolar bone loss [17].
Although dental implants have been widely used in clinical
settings, opinions regarding implants for CKD patients vary. Both
the oral and nephrological literature suggests that dental implant
surgery may be contraindicated in patients with significant renal
osteodystrophy [18,19]. However, other investigations into the
quantity and quality of the alveolar bone of dialysis patients
showed that the residual bone volumes were adequate for implant
insertion, suggesting this type of treatment is applicable to CKD
patients [20]. Previously, we studied the effect of CKD on
osseointegration of titanium implants using a uremic mouse
model. Although all implants were able to be successfully
integrated, CKD significantly decreased the bone-implant strength
at an early stage in healing [21]. Therefore, enhancement of
dental implant osseointegration in CKD patients remains a
challenge.
Vitamin D deficiency is common in CKD patients [22–26] and
this deficiency may negatively affect bone regeneration and
fracture healing due to its importance in bone metabolism [27].
Low serum 1,25-dihydroxyvitamin D triggers higher levels of
serum PTH [28,29], which in turn promotes high bone turnover,
exacerbates osteopenia and finally results in cortical bone loss and
pathogenesis of osteoporosis [30–32]. Kelly et al. [15] showed that
vitamin D insufficiency impairs the osseointegration of Ti6Al4V
implants in male Sprague-Dawley rats. Alvim-Pereira F et al. [33]
observed no association between a vitamin D receptor polymor-
phism (rs731236, TaqI) and dental implant loss. On the other
hand, vitamin D supplementation has demonstrated a significant
survival advantage in CKD patients [25], and accelerated cellular
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suggest a potentially beneficial role for vitamin D in promoting
implant osseointegration in CKD patients. In this study, we
established a CKD mouse model to investigate the effect of
vitamin D supplementation on fixation of titanium implants. The
results are expected to be a significant contribution to dental
implant therapy in CKD patients.
Materials and Methods
Ethics Statement
This study was carried out in strict accordance with the
recommendations contained in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health and the
ARRIVE guidelines (http://www.nc3rs.org/ARRIVE). All of the
experiments performed were approved by the Subcommittee on
Research and Animal Care (SRAC), which serves as the
Institutional Animal Care and Use Committee (IACUC) at the
Harvard Medical School (protocol number: 03901). All surgery
was performed under anesthesia by intraperitoneal injection of a
combination of ketamine (100 mg/ml) and xylazine (10 mg/ml),
in addition, buprenorphine (0.05 mg/kg) was given for perioper-
ative analgesia to minimize suffering and pain.
Animals
Thirty 9-week-old female C57BL mice (body weight: 22.0+
2.0 g) were obtained from Charles River Laboratories Interna-
tional Inc. (Wilmington, MA) and randomly assigned to three
groups: control(n=10), CKD(n=10), and CKD+Vit D(n=10).
The animals were kept under climate-controlled conditions (25uC;
55% humidity; 12 hours of light alternating with 12 hours of
darkness) and fed with a standard diet.
Surgical Procedure to Induce Uremia
CKD is induced in mice by a two-step 5/6 nephrectomy to
produce uremia as described previously [21]. Briefly, the first
procedure involves electrocautery of the left kidney except for a 2-
mm area around the hilum. After 1 week, a total nephrectomy of
the right kidney is performed by ligation of the renal hilum and
surgical excision. Sham surgery consists of anesthetic administra-
tion, flank incision exposing the kidney, and closure of the
abdominal wall.
Supplement of Active Vitamin D
The active form of vitamin D [1,25(OH)2D3], was obtained
from Enzo Life Sciences Inc. (Farmingdale, NY) and diluted in
saline. Eight weeks after the second kidney surgery, mice in the Vit
D-treated group were injected with Vit D (100 ng/kg body weight)
3 times a week until they were sacrificed. Saline was used as a
vehicle. The workflow is shown in Fig. S1.
Implant Surgery
Ten weeks after the second surgery (renal ablation), the mice
were subjected to implant placement using the method described
by Xu et al. [35]. Titanium implants with SLA surface (1 mm in
diameter and 4 mm in length) were obtained from Institut
Straumann AG (Basel, Switzerland). They were cut to the length
of 2 mm before insertion. After careful exposure of the distal
aspects of the femurs via skin incision and muscle dissection,
implant sites were prepared on both sides of the anterior-distal
surfaces of the femurs by sequential drilling under cooled sterile
saline irrigation with 0.7- and 1.0-mm surgical stainless steel twist
drills. Then, the implants were press-fitted into the holes to reach
primary stability. After the insertion of the implant, the muscles
were carefully sutured with 6-0 silk, which covered the implant
and further guaranteed its protection in the biological environ-
ment. Then the skin was closed with 5-0 silk.
Serum Biochemical Assays
Two weeks after the insertion of titanium implants, the mice
were euthanized by carbon dioxide inhalation. Prior to euthanasia,
blood was collected by cheek pouch puncture. Serum biochemistry
was performed using commercially available kits: blood urea
nitrogen (BUN) (Roche Diagnostics, Indianapolis, IN);
1,25(OH)2D (Immunodiagnostic Systems Ltd., Fountain Hills,
AZ); Calcium and Phosphate (Stanbio Laboratory, Boerne, TX).
For the assay of serum ALP activity, the serum was diluted 25
times and measured using a SensoLyte pNPP Alkaline Phosphatase
Assay Kit (AnaSpec Inc., Fremont, CA).
X-ray Examination and Histological Preparation
Two weeks after implant placement, one femur carrying an
implant was harvested from each mouse and fixed in 10% buffered
formalin for 1 week at 4uC. Specimens were exposed to X-ray
(20 kV, 5 seconds), and then dehydrated and embedded in light-
curing epoxy resin (TechnoVit 7200VLC, Hereaus Kulzer,
Wehrheim, Germany). Embedded specimens were cut perpendic-
ular to the longitudinal axis of the implants at a site 0.5 mm from
its apical end. The specimens were then ground to a thickness of
about 50 mm with a grinding system (Exakt Apparatebau,
Norderstedt, Germany). Sections were stained with Stevenel’s
blue and Van Gieson’s picro fuchsin stain, and observed by light
microscopy.
Histomorphometric Measurement
Images of the implant and peri-implant bone tissues were
digitized and histomorphometrically analyzed with NIH Image J
(National Institutes of Health, USA). Bone-implant contact (BIC)
was calculated as the linear percentage of direct bone-to-implant
contact to the total surface of the implant. And the bone volume
(BV/TV) in the circumferential zone within 100 mm of the
implant surface was calculated. The following formulas were used
for analysis.
Bone{implantcontact % ðÞ ~
sumof thelengthof bone=implantcontact ðÞ =
circumferenceof theimplant ðÞ |100%
Bonevolume~ boneareain100mmzone ðÞ =
areaof 100mmzone ðÞ |100%:
Implant Biomechanical Push-in Test
The remaining femur from each mouse was harvested and
embedded into auto-polymerizing resin with the top surface of the
implant level. A test machine (AG-TA electronic universal testing
machine, SHIMADZU, Japan) equipped with a pushing rod
(diameter=0.8 mm) was used to load the implant vertically
downward at a crosshead speed of 1 mm/min. The push-in value
was determined by measuring the peak of the load-displacement
curve.
Vit D Enhances Implant Fixation in CKD
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All values were presented as mean 6 SD. Statistically significant
differences were assessed by ANOVA followed by Tukey’s test for
multiple comparison, or by independent student t test for
comparison between two groups. A p value of less than 0.05 was
considered to be statistically significant.
Results
Animals
As anticipated, all mice tolerated the surgical procedures well
and survived the full experimental period. No inflammation or
infection at the implant site was observed.
Serum Biochemistry
A significant increase in serum BUN was observed in the CKD
(53.8766.32) and CKD+Vit D (58.4564.33) groups as compared
to that of controls (20.1263.46) (p,0.05), indicating the successful
establishment of the uremic mouse model (Figure S2A). Vit D
injections did not cause a significant change in the serum BUN
level. As shown in Figure S2B, Vit D was significantly decreased in
the CKD group (27.5168.35) (p,0.05), while supplementing with
Vit D (62.44626.88) restored it to levels comparable to those in
control mice (52.35616.33). Serum PTH in the CKD group was
3.6-fold that observed in the control group (p,0.05). It decreased
to the levels comparable to the control upon Vit D treatment
(Figure S2C). There was no significant difference in serum calcium
(Figure S2D) and phosphate (Figure S2E) levels among the three
groups. Serum ALP decreased significantly in the Vit D-treated
group as compared to the CKD group (p,0.05), although it was
still significantly higher than that of control (Figure S2F).
X-ray Examination
The ex vivo X-ray examination of the femurs showed that the
implants were surrounded with bone without any notable
radiotranslucent gap, indicating successful osseointegration in all
groups (Figure S3).
Histology and Histomorphometry
Examination of histological sections confirmed a direct bone-
implant contact in all groups (Figure S4A). Consistent with our
previous report [21], the CKD group showed a decrease of bone-
implant contact ratio (BIC) when compared to that of control. The
contact ratio was successfully restored to the normal level after Vit
D treatment. As shown in Figure S4B, the BIC of CKD+VitD
group was 75.2369.92, over 20% higher than that of CKD mice
(61.86610.11) (p,0.05). We then calculated the bone volume
(BV/TV) in the circumferential zone within 100 mm of the
implant surface and were able to observe a 35% increase after Vit
D treatment (Figure S4C).
The Resistance of Implant
In the early healing stage (week 2), the resistance of the implant
was significantly higher for the Vit D treated group (15.2164.11)
compared to that of the untreated CKD mice (9.8661.89),
indicating an improved strength of bone–implant integration
(Figure S5). No significant difference in integration was observed
between the control and CKD+VitD groups.
Discussion
Vitamin D is a pleiotropic hormone that plays a critical role in
regulating mineral ion metabolism [28]. It is initially biologically
inactive and requires sequential hydroxylations in the liver and
kidney to produce its active form, 1,25-dihydroxyvitamin D [28].
Vit D insufficiency is a common medical condition in CKD
patients [24], where declining renal function impairs the activity of
1-a hydroxylase (1a-OHase) in kidney, which in turn reduces its
ability to convert 25(OH)2D to its activated form, 1,25(OH)2D. In
this study, we established a uremic mouse model with significantly
reduced levels of 1,25(OH)2D using the 5/6 nephrectomy method.
These data are consistent with previous studies and similar to the
clinical situation in CKD patients [36,37].
Vitamin D deficiency negatively affects bone regeneration,
including fracture healing, due to its importance in bone
metabolism [27]. Moreover, Kelly et al. [15] showed that vitamin
D insufficiency decreased the bone-implant contact ratio and the
resistance in push-in tests. Recently, Choukroun et al. [38] found
that Vit D deficiency slows down the process of osseointegration,
and also promotes infection in the graft. A genome-wide screening
also suggested that Vit D deficiency affects the osseointegration of
implants by regulating the circadian rhythm system and the
cartilage extracellular matrix [39].
On the other hand, vitamin D supplementation has demon-
strated a significant survival advantage in CKD patients [25],
including accelerated cellular events in the process of fracture
healing [34]. Vitamin D supplementation has been recommended
as the primary therapy by the National Kidney Foundation to
control secondary hyperparathyroidism and prevent skeletal
complications in end stage renal failure patients [40,41]. Two
recent studies demonstrated that Vit D supplementation was able
to enhance implant fixation in diabetic mellitus rats with Vit D
insufficiency [42,43]. Similar results were reported in studies using
normal [44] or ovariectomized animals [45,46]. In this study, we
successfully corrected the decreased 1,25(OH)2D levels in CKD
mice by Vit D injection, and found that both the bone-implant
contact (BIC) ratio and the resistance of implant were significantly
increased after a 2-week healing period, indicating that Vit D
supplementation is an effective approach to improve fixation of
titanium implants in CKD.
We also found that Vit D supplementation successfully
corrected the increased levels of PTH, a key hormone for bone
remodeling. In CKD patients, low serum 1,25-dihydroxyvitamin
D triggers higher secretion of PTH [28,29], which precipitates
high bone turnover and exacerbates osteopenia and finally results
in bone loss [30–32]. A meta-analysis performed by Kandula et al.
[47] showed that any form of vitamin D (including calcitriol or a
vitamin D analog) lowers PTH levels in CKD patients. In this
context, we hypothesize that in addition to the direct impact of Vit
D on bone healing, the normalization of PTH levels might also
contribute to the enhancement of implant fixation. However the
direct effect of PTH on osseointegration in CKD needs to be
studied further.
It should be noted that this study was performed using a mouse
model with the implants placed in the distal end of femurs.
Although the rodent model has been widely used for research in
implant dentistry[42,45,46], the development and characterization
of the femur is different from the jaw bone. A canine or mini pig
model might be a better alternative as the implants can be inserted
in the jaw bone instead of the femur. However, the establishment
of CKD in these large animals is not yet well-established. Clinical
trials are expected to confirm whether supplement of Vit D could
be a good candidate for clinical approaches to enhance the fixation
of titanium implants in CKD patients.
Vit D Enhances Implant Fixation in CKD
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In this study, we found that Vit D supplementation successfully
restored serum 1,25(OH)2D levels and corrected the hyperpara-
thyroidism in CKD mice. The bone-implant contact ratio, bone
volume around implant and the resistance of the implant were
improved at 2 weeks after implantation, indicating that Vit D
supplementation is an effective approach to improve the fixation of
titanium implants in CKD.
Supporting Information
Figure S1 Illustration of the workflow. 1
st renal surgery:
electrocautery of the left kidney; 2
nd renal surgery: a total
nephrectomy of the right kidney; Vitamin D injections started at
9
th week (100 ng/kg body weight, 3 times a week for 4 weeks).
(TIF)
Figure S2 Serum biochemical measurements. (A) Serum
BUN; (B) Serum Vitamin D; (C) Serum PTH; (D) Serum calcium;
(E) Serum phosphate, and (F) Serum ALP activity. *: p,0.05 vs
Control; #: p,0.05 vs CKD.
(TIF)
Figure S3 X-ray examination of the femurs after 2-
weeks healing. The implants were surrounded with bone
without any notable radiotranslucent gap.
(TIF)
Figure S4 Histological and histomorphometrical analy-
sis of the implants after 2-week healing. (A) Representative
images of undecalified sections from all three groups; VitD
injection significantly increased (B) Bone-implant contact ratio
(BIC, %), and (C) bone volume (BV/TV) in the circumferential
zone within 100 mm of the implant surface. *: p,0.05 vs Control;
#: p,0.05 vs CKD.
(TIF)
Figure S5 Resistance of push-in tests 2 weeks after
implant placement. Vit D supplementation corrected the
resistance of implant in CKD. *: p,0.05 vs control; #: p,0.05 vs
CKD.
(TIF)
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